NOX 2.86% 7.2¢ noxopharm limited

From the quarterly report: NOX66 + LuPSMA much better than...

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    From the quarterly report:
    1. NOX66 + LuPSMA much better than LuPSMA alone
      1. Survival data for first 32 patients to be released 13 Feb
    2. NOX66 + EBRT responses clearly superior to current standard-of-care
      1. Multi-national, placebo controlled Phase 2b trial being organised
    3. NOX expects NOX66 to BECOME the standard-of-care
    4. NOX66 being used for compassionate treatment with either EBRT or LuPSMA
      1. Could they charge for this?
    5. New drug being developed to treat brain cancer
    6. Long-term funding likely to replace convertible notes
    NOX66 works.  I expect the share price to increase once the convertible note finance is replaced.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
7.2¢
Change
0.002(2.86%)
Mkt cap ! $21.04M
Open High Low Value Volume
7.2¢ 7.2¢ 7.2¢ $1.367K 18.99K

Buyers (Bids)

No. Vol. Price($)
1 72463 6.9¢
 

Sellers (Offers)

Price($) Vol. No.
7.2¢ 8810 1
View Market Depth
Last trade - 15.33pm 26/07/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.